



PRESS RELEASE

Adocia announces its financial calendar for 2016

Lyon, France, December 16, 2015 - Adocia (Euronext Paris: FR0011184241 - ADOC), a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins, especially insulins for diabetes treatment, announces today its financial calendar for 2016.

February 18, 2016:	Publication of revenue for Q4 2015 and for 2015 full year.
March 16, 2016:	Publication of 2015 financial statements (the Reference Document will be released during Q2 2016).
April 14, 2016:	Publication of revenue for Q1 2016.
June 21, 2016:	Annual shareholders' meeting.
July 20, 2016:	Publication of mid-year financial statements as of June 30, 2016.
October 13, 2016:	Publication of revenue for Q3 2016.

In addition to regular meetings with the financial community, investors can also find updated information on the company's website (www.adocia.com). All corporate information on the company such as its financial statements, its corporate presentation and its status is available on the company's website, in the Investors' section, « Regulated Information ».

About Adocia:

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia's insulin formulation portfolio, featuring four clinical-stage programs and one preclinical program, is among the largest and most differentiated in the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia's clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a fast-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a fast-acting insulin analog (BioChaperone Combo). Adocia is also developing a concentrated, rapid-acting formulation of human insulin (HinsBet U500).

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro programs.

Adocia's extended, early-stage programs include innovative monoclonal antibody formulations, featuring two ongoing collaborations programs with major pharmaceutical companies in the field, and the delivery of anticancer drugs using the proprietary DriveIn® nanotechnology platform.

Adocia aims to deliver "Innovative medicine for everyone, everywhere."

To learn more about Adocia, please visit us at www.adocia.com



For more information please contact:

<p>Adocia Gérard Soula Chairman and CEO contactinvestisseurs@adocia.com Tel.: +33 4 72 610 610</p>	<p>Adocia Press Relations ALIZE RP Caroline Carmagnol and Florence Portejoie caroline@alizerp.com adocia@alizerp.com Tel.: + 33 1 44 54 36 61</p>
--	---